CRIC Combined With MFT for Cardiovascular Adverse Events in Patients With Incomplete Revascularization of CAD

Recruiting now · Not applicable · Has a placebo group

Conditions studied: Coronary Artery Disease

In brief

The main objective of this study is to demonstrate whether the combination of chronic remote ischemic conditioning and mindfulness therapy can reduce cardiovascular adverse events in patients with incomplete revascularization of coronary artery disease.

Key facts

Study ID: NCT06820970
Run by: Henan Institute of Cardiovascular Epidemiology
People needed: 2000
Starts: 2025-08-01
Expected to finish: 2029-12-30
Last updated by the study team: 2026-04-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

1) Age ≥18 years old
2) Consistent with the diagnosis of coronary heart disease, complete revascularization was not performed (coronary angiography showed that at least one vessel with a reference diameter of 3.0mm had stenosis greater than 90%, and quantitative flow ratio (QFR) < 0.80)
3) Symptoms of myocardial ischemia (resting or exertional angina; Angina allele: chest tightness, shortness of breath, etc.);

You may not qualify if…

Age < 18 years old
Heart failure patients with NYHA class IV, or left ventricular ejection fraction (LVEF) < 30%
Creatinine clearance <15 mL/min (or eGFR < 15 mL/min/1.73m²), or requires dialysis
Myocardial diseases such as hypertrophic cardiomyopathy, dilated cardiomyopathy, etc.
Uncontrolled or recurrent arrhythmic events (e.g., ventricular fibrillation, recurrent or symptomatic sustained ventricular tachycardia, complete heart block, atrial fibrillation with rapid ventricular rates, supraventricular tachycardia refractory to drugs)
Poorly controlled hypertension (SBP > 180 mm Hg or DBP > 110 mm Hg)
Active liver disease or persistent ALT or AST elevation ≥ 3 times the upper limit of normal
Unexplained CK > 5 times the upper limit of normal, or elevated CK due to known muscle disease
Planned or anticipated cardiac surgery or revascularization before randomization
History of active malignancy (surgery, radiation therapy, and/or systemic therapy within the past 3 years)
Diagnosed or suspected upper extremity vascular malformations, aneurysms, arteriovenous fistulas, or thrombosis
Hearing impairment, unable to undergo mindfulness therapy
Currently participating in another drug or device study, or within 30 days of completing another drug or device study or receiving another investigational drug
Any life-threatening comorbid conditions expected to result in death within the next year (excluding cardiovascular diseases)
Alcoholism, substance abuse history; and unwilling or unable to stop alcohol or substance abuse during the study
History of major organ transplant (e.g., lung, liver, heart, bone marrow, kidney)
Investigator's judgment of known major active and uncontrolled disease, or any medical, physical, or surgical conditions (e.g., infection, significant blood, kidney, metabolic, gastrointestinal, or endocrine dysfunction) that may interfere with participation in the clinical study
As known to the investigator, the subject is unlikely to complete follow-up for more than 1 year or is expected to be unable to comply with the study requirements or understand the study's objectives and potential risks.

Where it is running

Fuwai Central China Cardiovascular Hospital — Zhengzhou, Henan, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.